E Fund Management Co., Ltd. Anavex Life Sciences Corp. Transaction History

E Fund Management Co., Ltd.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$3.39 - $5.02 $61,142 - $90,540	-18,036 Reduced 56.97%	13,623 $57,000
Q1 2024 May 13, 2024	BUY	$4.55 - $6.75 $87,683 - $130,079	19,271 Added 155.56%	31,659 $161,000
Q4 2023 Feb 06, 2024	SELL	$5.04 - $9.95 $7,660 - $15,123	-1,520 Reduced 10.93%	12,388 $115,000
Q3 2023 Nov 13, 2023	SELL	$6.55 - $9.37 $32,389 - $46,334	-4,945 Reduced 26.23%	13,908 $91,000
Q2 2023 Aug 11, 2023	SELL	$7.66 - $9.5 $57,917 - $71,829	-7,561 Reduced 28.62%	18,853 $153,000
Q1 2023 May 11, 2023	BUY	$8.32 - $11.75 $17,072 - $24,111	2,052 Added 8.42%	26,414 $226,000
Q4 2022 Feb 14, 2023	BUY	$7.65 - $14.43 $42,434 - $80,043	5,547 Added 29.48%	24,362 $226,000
Q3 2022 Nov 14, 2022	SELL	$8.9 - $12.86 $3,818 - $5,516	-429 Reduced 2.23%	18,815 $194,000
Q2 2022 Aug 15, 2022	BUY	$7.31 - $12.84 $5,679 - $9,976	777 Added 4.21%	19,244 $193,000
Q1 2022 May 12, 2022	BUY	$9.74 - $17.69 $131,645 - $239,098	13,516 Added 273.0%	18,467 $227,000
Q1 2021 May 12, 2021	BUY	$5.17 - $16.13 $25,596 - $79,859	4,951 New	4,951 $74,000

154

27.3M

515K

838K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $581M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.